Estudio de etiqueta abierta para evaluar la seguridad y eficacia de CABA-201 en sujetos con miopatía inflamatoria idiopática activa
Un estudio abierto de fase 1/2 para evaluar la seguridad y eficacia de las células T autólogas del receptor de antígeno quimérico específico de CD19 (CABA-201) en sujetos con miopatía inflamatoria idiopática activa
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Cabaletta Bio
- Número de teléfono: 4444 267-759-3100
- Correo electrónico: clinicaltrials@cabalettabio.com
Ubicaciones de estudio
-
-
-
Göttingen, Alemania, 37075
- Aún no reclutando
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Contacto:
- Dr. Jana Zschüntzsch
- Correo electrónico: j.zschuentzsch@med.uni-goettingen.de
-
Investigador principal:
- Dr. Jana Zschüntzsch
-
-
-
-
California
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- University of California Irvine - Accepting Adult Patients
-
Investigador principal:
- Tahseen Mozaffar, MD
-
Contacto:
- Alpha Clinic
- Número de teléfono: 949-824-3990
- Correo electrónico: alphaclinic@uci.edu
-
San Francisco, California, Estados Unidos, 94158
- Reclutamiento
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Contacto:
- Zilan Zheng
- Número de teléfono: 415-353-1301
- Correo electrónico: Zilan.Zheng@ucsf.edu
-
Investigador principal:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80046
- Reclutamiento
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Investigador principal:
- Dr. Kentaro Yomogida, MD
-
Contacto:
- Callie Strini - Primary Clinical Research Coordinator
- Número de teléfono: 720-777-9845
- Correo electrónico: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Reclutamiento
- Mayo Clinic Florida - Accepting Adult Patients
-
Contacto:
- Gabrielle Pariseau
- Número de teléfono: 904-953-5549
- Correo electrónico: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Estados Unidos, 33701
- Reclutamiento
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Investigador principal:
- Natalie Booth, DO
-
Contacto:
- Laura Escobar
- Número de teléfono: 727-767-2946
- Correo electrónico: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30032
- Reclutamiento
- Emory University - Accepting Adult Patients
-
Contacto:
- John Varghese
- Correo electrónico: john.varghese@emory.edu
-
Investigador principal:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Estados Unidos, 30029
- Reclutamiento
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Investigador principal:
- Shanmuganathan Chandrakasan, MD
-
Contacto:
- Judson Russell
- Número de teléfono: 404-785-7263
- Correo electrónico: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Investigador principal:
- Dr. George Georges, MD
-
Contacto:
- Kaitlin King
- Número de teléfono: 312-695-0990
- Correo electrónico: autoimmunesct@nm.org
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Investigador principal:
- Dr. Iazsmin Ventura, MD
-
Contacto:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Número de teléfono: 773-702-6619
- Correo electrónico: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Sub-Investigador:
- Dr. Cuoghi Edens, MD, FAAP
-
Contacto:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- Correo electrónico: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Contacto:
- Tyler Sorensen
- Número de teléfono: 312-277-6828
- Correo electrónico: tsorensen@luriechildrens.org
-
Investigador principal:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- University of Kansas Medical Center - Accepting Adult Patients
-
Contacto:
- Samantha Colgan
- Número de teléfono: 913-945-9938
- Correo electrónico: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- Reclutamiento
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Contacto:
- Julie Thompson
- Número de teléfono: 301-480-3191
- Correo electrónico: Julie.thompson@nih.gov
-
Investigador principal:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Investigador principal:
- Susan Prockop, MD
-
Contacto:
- Kyle McBrearty
- Número de teléfono: 617-355-2780
- Correo electrónico: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- Reclutamiento
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Contacto:
- Abigail Whalen
- Número de teléfono: 734-615-4466
- Correo electrónico: abigaiwh@med.umich.edu
-
Investigador principal:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55902
- Reclutamiento
- Mayo Clinic - Accepting Adult Patients
-
Contacto:
- Bridget Neja
- Número de teléfono: 507-266-9150
- Correo electrónico: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Contacto:
- Janvi Bhatia
- Número de teléfono: 212-774-2123
- Correo electrónico: bhatiaj@hss.edu
-
Investigador principal:
- David R. Fernandez, MD, PhD
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Investigador principal:
- Jae Park, MD
-
Contacto:
- Atifah Osrat
- Número de teléfono: 646-608-2091
- Correo electrónico: osrata1@mskcc.org
-
The Bronx, New York, Estados Unidos, 10467
- Reclutamiento
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Contacto:
- Emily Gillies
- Número de teléfono: 718-696-2402
- Correo electrónico: egillies@montefiore.org
-
Investigador principal:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Reclutamiento
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Investigador principal:
- Saira Sheikh, MD
-
Contacto:
- Leah Luizza
- Correo electrónico: leah.luizza@med.unc.edu
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Investigador principal:
- Kaveh Ardalan, MD, MS
-
Contacto:
- Lynn Rodgers, MS
- Número de teléfono: 919-668-2953
- Correo electrónico: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health & Science University - Accepting Adult Patients
-
Contacto:
- Katie Lewis
- Número de teléfono: 503-908-9724
- Correo electrónico: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Contacto:
- CARTintake@chop.edu
- Correo electrónico: CARTintake@chop.edu
-
Investigador principal:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Estados Unidos, 15261
- Reclutamiento
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Contacto:
- Carol Oriss
- Correo electrónico: orissca@upmc.edu
-
Investigador principal:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Contacto:
- Vibha Chauhan, PhD
- Número de teléfono: 412-692-7924
- Correo electrónico: Vibha.chauhan@chp.edu
-
Investigador principal:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Contacto:
- Tofi Soneye
- Número de teléfono: 817-883-4730
- Correo electrónico: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Investigador principal:
- Samuel John, MD
-
Contacto:
- Dr. Samuel John
- Correo electrónico: dtpteam@childrens.com
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Houston Methodist Hospital - Accepting Adult Patients
-
Contacto:
- Amelia A. Nounes, MSN, RN, CCRP
- Número de teléfono: 346-356-3639
- Correo electrónico: aanounes@houstonmethodist.org
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Investigador principal:
- Huifang (Linda) Lu, MD
-
Contacto:
- Christina Amos Briggs, BSN, RN
- Número de teléfono: 713-563-5076
- Correo electrónico: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Reclutamiento
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Contacto:
- Morgan Badgley - Research Coordinator
- Número de teléfono: 801-662-4812
- Correo electrónico: morgan.badgley@hsc.utah.edu
-
Investigador principal:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Reclutamiento
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Contacto:
- Dr. Susan Shenoi, MD, MS
- Número de teléfono: 206-987-2193
- Correo electrónico: susan.shenoi@SeattleChildrens.org
-
Investigador principal:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Aún no reclutando
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Investigador principal:
- Sara Sabbagh, DO
-
Contacto:
- Erin Hammelev - Research Coordinator
- Número de teléfono: 414-337-7064
- Correo electrónico: ehammele@mcw.edu
-
-
-
-
-
Roma, Italia, 00165
- Reclutamiento
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Contacto:
- Dr. Marco Becilli
- Número de teléfono: +39 0668592739
- Correo electrónico: marco.becilli@opbg.net
-
Investigador principal:
- Professor Franco Locatelli
-
-
-
-
-
London, Reino Unido, WC1N 3BG
- Reclutamiento
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Contacto:
- Dr. Pedro Machado, FRCP, PhD
- Número de teléfono: 020 3456 7890
- Correo electrónico: uclh.car-ttrials@nhs.net
-
Investigador principal:
- Dr. Pedro Machado, FRCP, PhD
-
London, Reino Unido, SE5 9RS
- Reclutamiento
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Contacto:
- Rheumatology Research Team
- Número de teléfono: 0628 0207 848 0214
- Correo electrónico: Kch-tr.CRDresearch@nhs.net
-
Investigador principal:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Reino Unido, WC1N 3JH
- Reclutamiento
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Contacto:
- Professor Despina Eleftheriou
- Número de teléfono: 020 7405 9200
- Correo electrónico: Despina.Eleftheriou@gosh.nhs.uk
-
Investigador principal:
- Professor Despina Eleftheriou
-
Manchester, Reino Unido, M13 9WL
- Reclutamiento
- Manchester Royal Infirmary - Accepting Adult Patients
-
Contacto:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Número de teléfono: 01612765052
- Correo electrónico: Eleni.Tholouli@mft.nhs.uk
-
Investigador principal:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Reino Unido, M6 8HD
- Reclutamiento
- Salford Royal Hospital - Accepting Adult Patients
-
Contacto:
- Michelle Beswick
- Número de teléfono: 07759 136787
- Correo electrónico: Rheumatology.Research@nca.nhs.uk
-
Investigador principal:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Otros nombres:
|
|
Experimental: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Otros nombres:
|
|
Experimental: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Periodo de tiempo: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Periodo de tiempo: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Periodo de tiempo: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Medical Director, Cabaletta Bio
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades del Sistema Nervioso
- Enfermedades Musculares
- Enfermedades Neuromusculares
- Enfermedades del tejido conectivo
- Enfermedades del sistema inmunológico
- Enfermedades de la piel
- Polimiositis
- Enfermedades de la piel y del tejido conectivo
- Enfermedades autoinmunes
- Dermatomiositis
- Miositis
- Químicos orgánicos
- Hidrocarburos
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Ciclofosfamida
- fludarabina
Otros números de identificación del estudio
Otros números de identificación del estudio
- CAB-201-002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .